Propanc Biopharma Inc (NASDAQ:PPCB) Short Interest Down 94.9% in May

Propanc Biopharma Inc (NASDAQ:PPCB) was the recipient of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 31,201 shares, a decrease of 94.9% from the May 14th total of 617,010 shares. Approximately 1.9% of the company’s shares are sold short. Based on an average trading volume of 90,333 shares, the short-interest ratio is presently 0.3 days.

Propanc Biopharma Stock Up 80.0%

Shares of PPCB traded up $1.08 during trading hours on Thursday, reaching $2.43. 174,158,426 shares of the company traded hands, compared to its average volume of 1,676,080. The company’s fifty day moving average price is $2.27 and its two-hundred day moving average price is $7.36. The company has a market capitalization of $5.54 million, a price-to-earnings ratio of -0.10 and a beta of 3.48. Propanc Biopharma has a 12 month low of $1.30 and a 12 month high of $270.25.

Institutional Investors Weigh In On Propanc Biopharma

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC bought a new stake in shares of Propanc Biopharma Inc (NASDAQ:PPCB) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned approximately 0.33% of Propanc Biopharma at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Propanc Biopharma presently has a consensus rating of “Sell”.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.